An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

N/AActive Not RecruitingNCT07459686

Pfizer1 enrolled

Overview

A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ulcerative Colitis (UC)

Interventions

VelsipityDRUG

2 milligrams(mg) tablet as provided in real world practice

Eligibility

Sex: ALLMin age: 0 Years

Medical Language ↔ Plain English

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded. 2. Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.

Locations (1)

Pfizer

Tokyo, Japan

Outcomes

Primary Outcomes

The incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions)

Time frame: Up to 52 weeks

Secondary Outcomes

Percentage of Participants With Symptomatic Remission

Time frame: 12 weeks and 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.